Saventic Health, a Warsaw-based startup focused on AI-driven rare disease diagnosis, has raised €1.9 million in bridge funding from international investors, led by 4growth VC, alongside Poland's NCBR Investment Fund and the U.S.-based TNI Fund.
The funding will facilitate the company’s expansion into markets such as Europe, South America, and Canada, while preparing for a larger Series A funding round.
Co-founder and CEO Szymon Piątkowski stated, "Our international presence confirms that our algorithms are effective and well-received by our clients and partners. The healthcare, biotechnology, and innovation sectors are currently building a completely new market from scratch, fueled by the AI revolution."
Founded in 2019, Saventic Health has developed 50 AI algorithms that have diagnosed over 200 individuals with rare conditions in the past year. The company collaborates with 11 of the 30 largest pharmaceutical firms and operates in over 30 clinics and hospitals across Poland, Germany, France, Brazil, and Canada.
The technology analyzes medical records to suggest potential rare disease diagnoses, significantly improving efficiency compared to traditional methods, which can take 7-12 years for an accurate diagnosis.
Plans for market entry include Austria, Sweden, Spain, and Italy, with ongoing projects in Brazil and new initiatives in Colombia and Peru. The company aims to enter the U.S. market after its Series A funding.
TNI Fund, which focuses on transformative healthcare technologies, considers Saventic Health’s solutions as pivotal for the future of healthcare. 4growth VC has also increased its investment, highlighting the company's global potential.